Alcon (ALC) Buys Neurotech for $550M, Adding FDA-Approved MacTel Therapy

Alcon, a Swiss eye care company, acquired privately held Neurotech Pharmaceuticals for $550M, potentially adding more contingent payments. The deal includes Encelto, an encapsulated cell therapy expected to be approved in 2025, according to Alcon. The acquisition aims to expand Alcon's therapeutic portfolio.

Alcon (SIX/NYSE:ALC) acquired Neurotech Pharmaceuticals for $550M, adding ENCELTO, a treatment for MacTel, to its retina portfolio. The FDA-approved therapy is expected to be modestly accretive to sales growth in 2027. Alcon anticipates slight dilution to EPS initially, with accretion expected later.

Alcon acquires Neurotech and ENCELTO, the only FDA-approved treatment for MacTel Type 2, a rare retinal disease. The deal expands Alcon's retina portfolio and is expected to be modestly accretive to net sales growth from 2027. ENCELTO is a surgical cell therapy for MacTel, with around 25,000 diagnosed patients in the US. Neurotech is a private biotech company.

Alcon's Brytly (apraclonidine 0.125%) received FDA approval for OTC red-eye relief. It will be available online and at major retailers soon. The drug shows effects in one minute, lasting up to 12 hours, and is approved for adults and children 12+.

Alcon (ALC, ALC.SW) received FDA approval for BRYTLY Redness Reliever Eye Drops, an OTC treatment for eye redness. The product starts working in one minute and lasts up to 12 hours. Alcon claims it lasts 50% longer than Lumify and is safe and effective. The company expects to launch BRYTLY at major retailers and online soon. ALC closed at $66.18 on Friday, down 0.60%.

Alcon (ALC) received FDA approval for Brytly, an OTC eye drop. The company claims it provides 12-hour redness relief, lasting 50% longer than Bausch + Lomb's (BLCO) Lumify. Studies suggest low risk of redness rebound and tachyphylaxis.